| Literature DB >> 32641940 |
Maryam Baharloui1, Sayed Ahmmad Mirshokraee1, Azam Monfared1, Mohammad Hassan Houshdar Tehrani2.
Abstract
Cancer disease is a great concern in the worldwide public health and current treatments do not give satisfactory results, so, developing novel therapeutic agents to combat cancer is highly demanded. Nowadays, anticancer peptides (ACPs) are becoming promising anticancer drug candidates. This is due to several advantages inherited in peptide molecules, such as being usually with small size, high activity, low immunogenicity, good biocompatibility, diversity of sequence, and more modification sites for functionalization. To get benefit of these merits, in this work, we synthesized a new series of triazole- based analogues with peptide scaffold by employing click chemistry and evaluated their anticancer activities against breast, colon cancer cell lines as well as fibroblast cells using MTT assay. Our results suggest that peptide scaffolds containing 1H-1, 2, 3-triazole ring group are toxic against colon and breast cancer cells viability, and this effect was more pronounced on MDA-MB-231 cells compared with MCF-7 breast cells. As a conclusion, these designed peptide analogues may be good and safe candidates as future anticancer agents.Entities:
Keywords: Cancer; Click chemistry; MTT assay; Peptide analogues; Triazole rings
Year: 2019 PMID: 32641940 PMCID: PMC6934984 DOI: 10.22037/ijpr.2019.111722.13320
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Examples of medicinal 1, 2, 3-triazole ring containing derivatives
Scheme 1Preparation 4-(4-phenyl-1H-1, 2, 3-triazol-1-yl) benzoic acid. 1) NaNO2 /HCl, NaN3. 2) CuSO4/ sodium ascorbate
Scheme 2Preparation of triazole peptide conjugate. 1) HOBt, DMAP, DIC, in DMF. 2) Piperazine,in DMF. 3) HOBt, DIC, in DMF. 4) TFA with scavengers
Figure 2Mass spectrum of the triazole-GLTSK peptide conjugate
Figure 3Mass spectrum of the triazole-GEGSGA peptide conjugate
Anticancer activity of pentapeptides GLTSK (C1), hexapeptide GEGSGA (C2) and their Triazole analogues on Colon cancer cell line HT-29, using MTT assay
|
| ||
|---|---|---|
|
|
| |
| C1 mother | 10 | 93.01 ± 1.01 |
| C1 mother | 100 | 93.06 ± 0.48 |
| C1 mother | 1000 | 92.31 ± 0.16 |
| C1 Triazole | 10 | 92.8 ± 0.16 |
| C1 Triazole | 100 | 92.67 ± 0.45 |
| C1 Triazole | 1000 | 92.36 ± 0.74 |
| C2 mother | 10 | 92.79 ± 0.54 |
| C2 mother | 100 | 93.01 ± 0.57 |
| C2 mother | 1000 | 92.66 ± 0.44 |
| C2 Triazole | 10 | 92.56 ± 0.28 |
| C2 Triazole | 100 | 92.34 ± 0.68 |
| C2 Triazole | 1000 | 91.87 ± 0.39 |
| Ciprofloxacin | 10 | 93.02 ± 0.47 |
| Ciprofloxacin | 100 | 93.01 ± 0.41 |
| Ciprofloxacin | 1000 | 92.56 ± 0.41 |
Anticancer activity of pentapeptides GLTSK (C1), hexapeptide GEGSGA (C2), their triazole derivatives on MCF-7, MDA- MB-231 and fibroblast cells (HFF-1), using MTT assay
|
| |||
|---|---|---|---|
|
|
|
|
|
| C1 (mother) | 50.11 ± 2.09 | 78.7 ± 1.60 | 4.41 ± 2.70 |
| C1Triazole | 59.76 ± 10.34 | 79.9 ± 0.49 | 3.11 ± 1.19 |
| C2 (mother) | 83.39 ± 0.84 | 79.32 ± 0.23 | 3.11 ± 1.19 |
| C2Triazole | 82.12 ± 0.48 | 81.22 ± 0.30 | 5.97 ± 1.62 |
| Ciprofloxacin | 76.41 ± 1.08 | 81.11 ± 0.23 | 2.33 ± 1.19 |